155 related articles for article (PubMed ID: 33811992)
1. Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO).
Hu CH; Neissel Valente MW; Halpern OS; Jusuf S; Khan JA; Locke GA; Duke GJ; Liu X; Duclos FJ; Wexler RR; Kick EK; Smallheer JM
Bioorg Med Chem Lett; 2021 Jun; 42():128010. PubMed ID: 33811992
[TBL] [Abstract][Full Text] [Related]
2. Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase.
Shaw SA; Vokits BP; Dilger AK; Viet A; Clark CG; Abell LM; Locke GA; Duke G; Kopcho LM; Dongre A; Gao J; Krishnakumar A; Jusuf S; Khan J; Spronk SA; Basso MD; Zhao L; Cantor GH; Onorato JM; Wexler RR; Duclos F; Kick EK
Bioorg Med Chem; 2020 Nov; 28(22):115723. PubMed ID: 33007547
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel indole pharmacophore for the irreversible inhibition of myeloperoxidase (MPO).
Patnaik A; Axford L; Deng L; Cohick E; Ren X; Loi S; Kecman S; Hollis-Symynkywicz M; Harrison TJ; Papillon JPN; Dales N; Hamann LG; Lee L; Regard JB; Marcinkeviciene J; Marro ML; Patterson AW
Bioorg Med Chem; 2020 Jun; 28(12):115548. PubMed ID: 32503688
[TBL] [Abstract][Full Text] [Related]
4. Characterization of chemical features of potent myeloperoxidase inhibitors.
Soubhye J; Meyer F; Furtmüller P; Obinger C; Dufrasne F; Antwerpen PV
Future Med Chem; 2016 Jul; 8(11):1163-77. PubMed ID: 27402298
[TBL] [Abstract][Full Text] [Related]
5. The development of myeloperoxidase inhibitors.
Galijasevic S
Bioorg Med Chem Lett; 2019 Jan; 29(1):1-7. PubMed ID: 30466896
[TBL] [Abstract][Full Text] [Related]
6. Novel bis-arylalkylamines as myeloperoxidase inhibitors: Design, synthesis, and structure-activity relationship study.
Aldib I; Gelbcke M; Soubhye J; Prévost M; Furtmüller PG; Obinger C; Elfving B; Alard IC; Roos G; Delporte C; Berger G; Dufour D; Zouaoui Boudjeltia K; Nève J; Dufrasne F; Van Antwerpen P
Eur J Med Chem; 2016 Nov; 123():746-762. PubMed ID: 27537923
[TBL] [Abstract][Full Text] [Related]
7. PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.
Dounay AB; Anderson M; Bechle BM; Evrard E; Gan X; Kim JY; McAllister LA; Pandit J; Rong S; Salafia MA; Tuttle JB; Zawadzke LE; Verhoest PR
Bioorg Med Chem Lett; 2013 Apr; 23(7):1961-6. PubMed ID: 23466229
[TBL] [Abstract][Full Text] [Related]
8. Non-oxime pyrazole based inhibitors of B-Raf kinase.
Newhouse BJ; Hansen JD; Grina J; Welch M; Topalov G; Littman N; Callejo M; Martinson M; Galbraith S; Laird ER; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
Bioorg Med Chem Lett; 2011 Jun; 21(11):3488-92. PubMed ID: 21536432
[TBL] [Abstract][Full Text] [Related]
9. Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).
Huynh T; Chen Z; Pang S; Geng J; Bandiera T; Bindi S; Vianello P; Roletto F; Thieffine S; Galvani A; Vaccaro W; Poss MA; Trainor GL; Lorenzi MV; Gottardis M; Jayaraman L; Purandare AV
Bioorg Med Chem Lett; 2009 Jun; 19(11):2924-7. PubMed ID: 19419866
[TBL] [Abstract][Full Text] [Related]
10. Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis.
Gomez L; Hack MD; Wu J; Wiener JJ; Venkatesan H; Santillán A; Pippel DJ; Mani N; Morrow BJ; Motley ST; Shaw KJ; Wolin R; Grice CA; Jones TK
Bioorg Med Chem Lett; 2007 May; 17(10):2723-7. PubMed ID: 17368897
[TBL] [Abstract][Full Text] [Related]
11. First triclosan-based macrocyclic inhibitors of InhA enzyme.
Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
[TBL] [Abstract][Full Text] [Related]
12. The soluble curcumin derivative NDS27 inhibits superoxide anion production by neutrophils and acts as substrate and reversible inhibitor of myeloperoxidase.
Franck T; Aldib I; Zouaoui Boudjeltia K; Furtmüller PG; Obinger C; Neven P; Prévost M; Soubhye J; Van Antwerpen P; Mouithys-Mickalad A; Serteyn D
Chem Biol Interact; 2019 Jan; 297():34-43. PubMed ID: 30342014
[TBL] [Abstract][Full Text] [Related]
13. Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.
Forbes LV; Sjögren T; Auchère F; Jenkins DW; Thong B; Laughton D; Hemsley P; Pairaudeau G; Turner R; Eriksson H; Unitt JF; Kettle AJ
J Biol Chem; 2013 Dec; 288(51):36636-47. PubMed ID: 24194519
[TBL] [Abstract][Full Text] [Related]
14. Pyrazoles as non-classical bioisosteres in prolylcarboxypeptidase (PrCP) inhibitors.
Graham TH; Shu M; Verras A; Chen Q; Garcia-Calvo M; Li X; Lisnock J; Tong X; Tung EC; Wiltsie J; Hale JJ; Pinto S; Shen DM
Bioorg Med Chem Lett; 2014 Apr; 24(7):1657-60. PubMed ID: 24636945
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
Leurs U; Clausen RP; Kristensen JL; Lohse B
Bioorg Med Chem Lett; 2012 Sep; 22(18):5811-3. PubMed ID: 22917519
[TBL] [Abstract][Full Text] [Related]
16. Inhibitive Effects of Quercetin on Myeloperoxidase-Dependent Hypochlorous Acid Formation and Vascular Endothelial Injury.
Lu N; Sui Y; Tian R; Peng YY
J Agric Food Chem; 2018 May; 66(19):4933-4940. PubMed ID: 29708335
[TBL] [Abstract][Full Text] [Related]
17. Flavonoids as substrates and inhibitors of myeloperoxidase: molecular actions of aglycone and metabolites.
Shiba Y; Kinoshita T; Chuman H; Taketani Y; Takeda E; Kato Y; Naito M; Kawabata K; Ishisaka A; Terao J; Kawai Y
Chem Res Toxicol; 2008 Aug; 21(8):1600-9. PubMed ID: 18620432
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors.
Soubhye J; Aldib I; Elfving B; Gelbcke M; Furtmüller PG; Podrecca M; Conotte R; Colet JM; Rousseau A; Reye F; Sarakbi A; Vanhaeverbeek M; Kauffmann JM; Obinger C; Nève J; Prévost M; Zouaoui Boudjeltia K; Dufrasne F; Van Antwerpen P
J Med Chem; 2013 May; 56(10):3943-58. PubMed ID: 23581551
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Guaiacol Derivatives as Promising Myeloperoxidase Inhibitors Targeting Atherosclerotic Cardiovascular Disease.
Premkumar J; Sampath P; Sanjay R; Chandrakala A; Rajagopal D
ChemMedChem; 2020 Jul; 15(13):1187-1199. PubMed ID: 32368837
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Biological Evaluation of Novel Aryl-2H-pyrazole Derivatives as Potent Non-purine Xanthine Oxidase Inhibitors.
Sun ZG; Zhou XJ; Zhu ML; Ding WZ; Li Z; Zhu HL
Chem Pharm Bull (Tokyo); 2015; 63(8):603-7. PubMed ID: 26040271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
